Contineum Therapeutics Management
Management criteria checks 0/4
Contineum Therapeutics' CEO is Carmine Stengone, appointed in Oct 2018, has a tenure of 6.58 years. total yearly compensation is $4.90M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 0.05% of the company’s shares, worth $49.57K. The average tenure of the management team and the board of directors is 1.1 years and 2.3 years respectively.
Key information
Carmine Stengone
Chief executive officer
US$4.9m
Total compensation
| CEO salary percentage | 12.41% |
| CEO tenure | 6.6yrs |
| CEO ownership | 0.05% |
| Management average tenure | 1.1yrs |
| Board average tenure | 2.3yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$50m |
| Dec 31 2024 | US$5m | US$608k | -US$42m |
| Sep 30 2024 | n/a | n/a | -US$29m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$5m |
| Dec 31 2023 | US$2m | US$516k | US$3m |
Compensation vs Market: Carmine's total compensation ($USD4.90M) is above average for companies of similar size in the US market ($USD645.28K).
Compensation vs Earnings: Carmine's compensation has increased whilst the company is unprofitable.
CEO
Carmine Stengone (48 yo)
Mr. Carmine N. Stengone, MS, MBA, serves as Chief Executive Officer, President & Director of Contineum Therapeutics, Inc. since October 2018 and served as its Secretary and served as its Chairman of the Bo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$4.90m | 0.050% $ 49.6k | |
| General Counsel & Corporate Secretary | less than a year | US$2.74m | no data | |
| Chief Financial Officer | 4.6yrs | US$1.03m | 0% $ 0 | |
| Senior Manager of Accounting | 1.3yrs | no data | no data | |
| Chief Science Officer | 7.2yrs | US$1.79m | 0.67% $ 664.8k | |
| Senior Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Vice President of Human Resources | less than a year | no data | no data | |
| Senior VP & Head of Research | no data | no data | no data | |
| Senior Vice President of Clinical Operations | less than a year | no data | no data | |
| Chief Medical Officer & Head of Development | less than a year | no data | no data |
Experienced Management: CTNM's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$4.90m | 0.050% $ 49.6k | |
| Independent Director | 1yr | US$424.21k | no data | |
| Independent Director | less than a year | US$505.57k | no data | |
| Director | less than a year | no data | 0.019% $ 19.3k | |
| Clinical Advisor | no data | no data | no data | |
| Independent Director | 1.2yrs | US$484.40k | 0.067% $ 66.7k | |
| Independent Chairman of the Board | 3.3yrs | US$482.97k | 0.16% $ 160.0k | |
| Independent Director | 4.8yrs | US$431.35k | 0.16% $ 154.7k | |
| Independent Director | 5.5yrs | US$831.41k | 0.10% $ 102.6k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
Experienced Board: CTNM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 20:02 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Contineum Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Debanjana Chatterjee | JonesTrading Institutional Services, LLC |
| Sean Laaman | Morgan Stanley |